ARTICLE | Product Development
Next-generation DNA damage response programs at AACR
April 15, 2021 1:10 AM UTC
Clinical readouts for WEE1 inhibitors, next-generation compounds against PARP and a pair of agents targeting CDC7 were among the DNA damage response programs featured at AACR this year.
This year’s virtual meeting of the American Association for Cancer Research (AACR) featured at least 14 company programs targeting regulators of the DDR pathway, a synthetic lethality-focused target space that took off with the success of PARP inhibitors and has continued to gain momentum through next-wave targets like ATR...